Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 28

1.

130th anniversary of Institut Pasteur: celebrating science.

Gougeon ML, Schwartz M, Brunner T, Ojcius DM.

Genes Immun. 2019 May;20(5):342-343. doi: 10.1038/s41435-019-0070-3. Epub 2019 Apr 25. No abstract available.

PMID:
31019251
2.

Message from the new Editors-in-Chief.

Brunner T, Gougeon ML.

Genes Immun. 2019 Apr;20(4):338-339. doi: 10.1038/s41435-018-0043-y. Epub 2018 Aug 17. No abstract available.

PMID:
30115974
3.

Anticancer chemotherapy and radiotherapy trigger both non-cell-autonomous and cell-autonomous death.

Martins I, Raza SQ, Voisin L, Dakhli H, Allouch A, Law F, Sabino D, De Jong D, Thoreau M, Mintet E, Dugué D, Piacentini M, Gougeon ML, Jaulin F, Bertrand P, Brenner C, Ojcius DM, Kroemer G, Modjtahedi N, Deutsch E, Perfettini JL.

Cell Death Dis. 2018 Jun 18;9(7):716. doi: 10.1038/s41419-018-0747-y.

4.

CHRONOVAC VOYAGEUR: A study of the immune response to yellow fever vaccine among infants previously immunized against measles.

Goujon C, Gougeon ML, Tondeur L, Poirier B, Seffer V, Desprès P, Consigny PH, Vray M; study group.

Vaccine. 2017 Oct 27;35(45):6166-6171. doi: 10.1016/j.vaccine.2017.09.047. Epub 2017 Sep 25.

PMID:
28958813
5.

Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1/2 clinical trial.

Tardieu M, Zérah M, Gougeon ML, Ausseil J, de Bournonville S, Husson B, Zafeiriou D, Parenti G, Bourget P, Poirier B, Furlan V, Artaud C, Baugnon T, Roujeau T, Crystal RG, Meyer C, Deiva K, Heard JM.

Lancet Neurol. 2017 Sep;16(9):712-720. doi: 10.1016/S1474-4422(17)30169-2. Epub 2017 Jul 14.

PMID:
28713035
6.

Erratum to 'HMGB1/anti-HMGB1 antibodies define a molecular signature of early stages of HIV-Associated Neurocognitive Disorders (HAND)'.

Gougeon ML, Poirier-Beaudouin B, Durant J, Lebrun-Frenay C, Saïdi H, Seffer V, Ticchioni M, Chanalet S, Carsenti H, Harvey-Langton A, Laffon M, Cottalorda J, Pradier C, Dellamonica P, Vassallo M.

Heliyon. 2017 Mar 16;3(3):e00259. doi: 10.1016/j.heliyon.2017.e00259. eCollection 2017 Mar.

7.

HMGB1/anti-HMGB1 antibodies define a molecular signature of early stages of HIV-Associated Neurocognitive Isorders (HAND).

Gougeon ML, Poirier-Beaudouin B, Durant J, Lebrun-Frenay C, Saïdi H, Seffer V, Ticchioni M, Chanalet S, Carsenti H, Harvey-Langton A, Laffon M, Cottalorda J, Pradier C, Dellamonica P, Vassallo M.

Heliyon. 2017 Feb 13;3(2):e00245. doi: 10.1016/j.heliyon.2017.e00245. eCollection 2017 Feb. Erratum in: Heliyon. 2017 Mar 16;3(3):e00259.

8.

HMGB1 Is Involved in IFN-α Production and TRAIL Expression by HIV-1-Exposed Plasmacytoid Dendritic Cells: Impact of the Crosstalk with NK Cells.

Saïdi H, Bras M, Formaglio P, Melki MT, Charbit B, Herbeuval JP, Gougeon ML.

PLoS Pathog. 2016 Feb 12;12(2):e1005407. doi: 10.1371/journal.ppat.1005407. eCollection 2016 Feb.

9.

Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death.

Garg AD, Galluzzi L, Apetoh L, Baert T, Birge RB, Bravo-San Pedro JM, Breckpot K, Brough D, Chaurio R, Cirone M, Coosemans A, Coulie PG, De Ruysscher D, Dini L, de Witte P, Dudek-Peric AM, Faggioni A, Fucikova J, Gaipl US, Golab J, Gougeon ML, Hamblin MR, Hemminki A, Herrmann M, Hodge JW, Kepp O, Kroemer G, Krysko DV, Land WG, Madeo F, Manfredi AA, Mattarollo SR, Maueroder C, Merendino N, Multhoff G, Pabst T, Ricci JE, Riganti C, Romano E, Rufo N, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Vacchelli E, Vandenabeele P, Vandenberk L, Van den Eynde BJ, Van Gool S, Velotti F, Zitvogel L, Agostinis P.

Front Immunol. 2015 Nov 20;6:588. doi: 10.3389/fimmu.2015.00588. eCollection 2015.

10.

Immunogenicity and Safety of Influenza Vaccine in Inflammatory Bowel Disease Patients Treated or not with Immunomodulators and/or Biologics: A Two-year Prospective Study.

Launay O, Abitbol V, Krivine A, Slama LB, Bourreille A, Dupas JL, Hébuterne X, Savoye G, Deplanque D, Bouhnik Y, Pelletier AL, Galtier F, Laharie D, Nachury M, Zerbib F, Allez M, Bommelaer G, Duclos B, Lucht F, Gougeon ML, Tartour E, Rozenberg F, Hanslik T, Beaugerie L, Carrat F; MICIVAX Study Group.

J Crohns Colitis. 2015 Dec;9(12):1096-107. doi: 10.1093/ecco-jcc/jjv152. Epub 2015 Sep 7.

PMID:
26351392
11.

Thimerosal compromises human dendritic cell maturation, IL-12 production, chemokine release, and T-helper polarization.

Loison E, Gougeon ML.

Hum Vaccin Immunother. 2014;10(8):2328-35. doi: 10.4161/hv.29520.

12.

Causal analysis of H1N1pdm09 influenza infection risk in a household cohort.

Mansiaux Y, Salez N, Lapidus N, Setbon M, Andreoletti L, Leruez-Ville M, Cauchemez S, Gougeon ML, Vély F, Schwarzinger M, Abel L, Delabre RM, Flahault A, de Lamballerie X, Carrat F.

J Epidemiol Community Health. 2015 Mar;69(3):272-7. doi: 10.1136/jech-2014-204678. Epub 2014 Nov 21.

13.

Peripheral and local human papillomavirus 16-specific CD8+ T-cell expansions characterize erosive oral lichen planus.

Viguier M, Bachelez H, Poirier B, Kagan J, Battistella M, Aubin F, Touzé A, Carmagnat M, Francès C, Gougeon ML, Fazilleau N.

J Invest Dermatol. 2015 Feb;135(2):418-424. doi: 10.1038/jid.2014.397. Epub 2014 Sep 10.

14.

Suppression by thimerosal of ex-vivo CD4+ T cell response to influenza vaccine and induction of apoptosis in primary memory T cells.

Loison E, Poirier-Beaudouin B, Seffer V, Paoletti A, Abitbol V, Tartour E, Launay O, Gougeon ML.

PLoS One. 2014 Apr 1;9(4):e92705. doi: 10.1371/journal.pone.0092705. eCollection 2014.

15.

Clinical validation of IFNγ/IL-10 and IFNγ/IL-2 FluoroSpot assays for the detection of Tr1 T cells and influenza vaccine monitoring in humans.

Chauvat A, Benhamouda N, Gey A, Lemoine FM, Paulie S, Carrat F, Gougeon ML, Rozenberg F, Krivine A, Cherai M, Lehmann P 5th, Quintin-Colonna F, Launay O, Tartour E.

Hum Vaccin Immunother. 2014;10(1):104-13. doi: 10.4161/hv.26593. Epub 2013 Oct 1.

16.

Analysis of NKp30/NCR3 isoforms in untreated HIV-1-infected patients from the ANRS SEROCO cohort.

Prada N, Antoni G, Commo F, Rusakiewicz S, Semeraro M, Boufassa F, Lambotte O, Meyer L, Gougeon ML, Zitvogel L.

Oncoimmunology. 2013 Mar 1;2(3):e23472.

17.

IFN-α and TRAIL: a double edge sword in HIV-1 disease?

Gougeon ML, Herbeuval JP.

Exp Cell Res. 2012 Jul 1;318(11):1260-8. doi: 10.1016/j.yexcr.2012.03.012. Epub 2012 Mar 26. Review.

PMID:
22480868
18.

Natural killer cells, dendritic cells, and the alarmin high-mobility group box 1 protein: a dangerous trio in HIV-1 infection?

Gougeon ML, Bras M.

Curr Opin HIV AIDS. 2011 Sep;6(5):364-72. doi: 10.1097/COH.0b013e328349b089. Review.

PMID:
21825870
19.

Escape of HIV-1-infected dendritic cells from TRAIL-mediated NK cell cytotoxicity during NK-DC cross-talk--a pivotal role of HMGB1.

Melki MT, Saïdi H, Dufour A, Olivo-Marin JC, Gougeon ML.

PLoS Pathog. 2010 Apr 15;6(4):e1000862. doi: 10.1371/journal.ppat.1000862.

20.

HMGB1-dependent triggering of HIV-1 replication and persistence in dendritic cells as a consequence of NK-DC cross-talk.

Saïdi H, Melki MT, Gougeon ML.

PLoS One. 2008;3(10):e3601. doi: 10.1371/journal.pone.0003601. Epub 2008 Oct 31.

Supplemental Content

Loading ...
Support Center